

317

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/085391 A1

(51) International Patent Classification⁷: **C07D 207/34,**
A61K 31/00, A61P 3/06

JUHÁSZ, Ida [HU/HU]; Kalap u. 6., H-1037 Budapest (HU). **BÁLINT, Sándorné** [HU/HU]; Sasadi út 155., H-1112 Budapest (HU).

(21) International Application Number:
PCT/HU2004/000026

(74) Common Representative: **RICHTER GEDEON VEGYÉSZETI GYÁR RT.**; Gyömrői út 19-21., H-1103 Budapest (HU).

(22) International Filing Date: 23 March 2004 (23.03.2004)

(25) Filing Language: English

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
P0300761 24 March 2003 (24.03.2003) HU

(71) Applicant (for all designated States except US): **RICHTER GEDEON VEGYÉSZETI GYÁR RT.** [HU/HU]; Gyömrői út 19-21., H-1103 Budapest (HU).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **CZIBULA, László** [HU/HU]; Gergely u. 48., H-1103 Budapest (HU). **DOBAY, László** [HU/HU]; Kertész u. 42-44., H-1073 Budapest (HU). **WERKNÉ PAPP, Éva** [HU/HU]; Noszolpy u. 41., H-1103 Budapest (HU). **DEUTSCHNÉ**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KH, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IL, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PROCESS FOR THE SYNTHESIS OF AMORPHOUS ATORVASTATIN CALCIUM



(57) Abstract: The invention relates to a new process for the synthesis of amorphous atorvastatin calcium, which consists of dissolving the salt of the formula (I) of atorvastatin acid formed with a basic amino acid (I); in a mixture of water and a water miscible organic solvent, adding an aqueous solution of a water soluble calcium salt to the solution and isolating the so obtained entirely amorphous atorvastatin calcium of high purity by filtration.

WO 2004/085391 A1

**Declaration under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations *AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW*, *ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)*, *Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)*, *European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,*

LU, MC, NI, PL, PT, RO, SE, SI, SK, TR), *OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

Published:

- with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Process for the synthesis of amorphous atorvastatin calcium

The invention relates to a new process for the synthesis of amorphous atorvastatin calcium.

5 Atorvastatin calcium (its chemical name is: [R-(R*, R*)]-2-(4-fluorophenyl)-
β,δ-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-[(amino)-carbonyl]-1H-pyrrol-1-heptanoic
acid hemi-calcium salt) is known as a very efficient cholesterol level decreasing
compound acting as an inhibitor of 3-hydroxy-3-methyl-glutamine-coenzim "A"
reductase enzyme.

10 Atorvastatin calcium – as a new chemical entity – is first described in the US
Pat. Specification 5,273,995. However, there is no information about the crystal form
of the product in this description. Later on four different crystal modifications of
atorvastatin calcium have been described in the literature, the morphological
characterization and the synthesis of which are given in patent applications WO
15 97/03958 and WO 97/03959.

It is important to know that the amorphous atorvastatin calcium, which became
known meanwhile, has better bioavailability than the crystalline forms. Unambiguous
data support, that amorphous modification has more favourable features, for example
better dissolution properties, than the crystalline one [see: Konno I. : Chem. Pharm.
20 Bull., 38, 2003-2007 (1990)].

According to the above mentioned facts there is a need for elaborating a
process for the synthesis of amorphous atorvastatin calcium. The common feature of the
known procedures is that the entirely amorphous form of the atorvastatin calcium is
obtained from one of the crystalline forms, or a mixture of the different crystalline
25 forms or a mixture of the partially crystalline and partially amorphous form.

According to the patent application WO 97/07960 the amorphous atorvastatin
calcium is obtained from the so-called crystal form I, in an organic solvent, which does
not contain hydroxy group – for example tetrahydrofuran or a mixture of
tetrahydrofuran and toluene – applying complicated, tiresome technology of several
30 days.

According to the patent application WO 00/71116 any form of crystalline atorvastatin calcium is dissolved in a solvent, which does not contain hydroxy group (for example THF), then an apolar solvent is added (for example hexane, cyclohexane or heptane) to give the amorphous product, which is isolated by filtration.


5 According to an other solution (see: patent application WO 01/28999) the crude atorvastatin calcium – in contrast to the above procedures – is dissolved in a C₂₋₄ alcohol or a mixture of alcohols at the boiling point, the solution is cooled and the amorphous product is filtered.

According to the patent application Number of WO 01/42239 the crystal form I
10 – which is most difficult to obtain – is transformed into amorphous atorvastatin calcium the following way: the crystalline form is dissolved in a solvent (so-called type 1), for example methanol, ethanol or acetone, and from this very dilute solution the product is precipitated by addition of an other solvent (so-called type 2), for example ether.



The disadvantages of the above procedures are that the applied starting
15 material, the atorvastatin calcium, is obtained by a complicated, long technology and laborious isolation process, the used dilute solutions require large amount of solvents and the isolation of the amorphous product is very tiresome.

Our aim was to elaborate a simple, economical, industrially applicable process for the synthesis of entirely amorphous atorvastatin calcium of high purity.

20 In our experiments surprisingly it was found that entirely amorphous atorvastatin calcium of high purity can be obtained from some basic salts of atorvastatin of formula (I):



wherein the meaning of R is the compound of formula (II) or (III)



5

in concentrated, aqueous solution – without isolation or separation of the free acid – in one step, with simple technology. This result was unexpected, because according to the literature data (see for example the patent application WO 97/03959) in the presence of water always one of the crystalline polymorph modifications of the product was obtained. The observation of the present invention results in that the desired product can be synthesized – in contrast to the known procedures – in more concentrated solutions (10-15 w/w %) directly from one of the basic salts of the atorvastatin acid.

According to the above mentioned facts the invention relates to a process for the synthesis of amorphous atorvastatin calcium, which consists of dissolving the salt of the formula (I) of atorvastatin acid formed with a basic amino acid – wherein the meaning of R is the compound of formula (II) or (III) – in a mixture of water and a water miscible organic solvent, adding an aqueous solution of a water soluble calcium salt to the solution and isolating the so obtained entirely amorphous atorvastatin calcium of high purity by filtration.

The salts of atorvastatin acid formed with basic amino acids used in the synthesis according to our invention are atorvastatin L-lysine or atorvastatin L-arginine salts.

The water soluble calcium salts used in the process according to our invention are preferably calcium acetate or calcium chloride.

The water miscible organic solvents used in the process according to our invention are preferably methanol, ethanol, isopropanol or acetone.

According to the process of our invention the desired amorphous final product can be obtained in good yield, chemically pure, with simple technology. The chemical
5 purity of the obtained product was proved by HPLC method, which is described in example 4A and an HPLC chromatogram is also shown. From the chromatography it can be seen that the purity of the product is 99.90 w/w %, it is suitable for producing a pharmaceutical composition. The obtained product contains only three by-products and the amount of each is less than 0.1 w/w %.

10 The morphological purity of the product obtained according to the process of our invention was checked by X-ray diffraction method. The so obtained powder diagram (see Figure 1) proved that the product obtained according to the process of our invention is in 100 w/w % amorphous.

The solvent used in the process of our invention is a mixture of water and a
15 water miscible organic solvent, preferably methanol, ethanol, isopropanol or acetone.

The process of our invention is illustrated in details by the following not limiting examples:

Examples:

20 Example 1

Synthesis of amorphous atorvastatin calcium

16 g of L-lysine salt of atorvastatin is dissolved in a mixture of 437 ml of distilled water and 91.5 ml of ethanol at 35-40 °C, the solution is filtered and a filtered
25 solution of 1.92 g of calcium acetate hydrate in 20 ml of distilled water is added. The mixture is cooled to 0-5 °C and filtered immediately, the product is washed with a 5:1 mixture of water and ethanol (2x15 ml), and dried at max. 50 °C.

The obtained product is 12.9 g (yield: 98 w/w %)

The chemical purity of the product is: 99.92 %

30 Total amount of impurities is: below 0.08 %

The morphological purity of the product (according to X-ray diffraction study):
100% amorphous (see Figure 1)

Example 2

Synthesis of amorphous atorvastatin calcium

5 14 kg of L-lysine salt of atorvastatin is dissolved in a mixture of 60 liter of acetone and 60 liter of ion-exchanged water at 15-20 °C. A solution of 1.8 kg of calcium acetate hydrate in 18 liter of ion-exchanged water is added to the solution at the same temperature and the obtained suspension is stirred at 15-20 °C for 1 h. The product is centrifuged, washed with a 1:1 mixture of acetone and water (10 liter) and
10 dried at max. 50 °C.

Yield: 10.1 kg (88 %) amorphous atorvastatin calcium

The chemical purity of the product is: 99.87 % (see Example 5)

Total amount of impurities is: below 0.13 %

3 individual impurities: 0.03; 0.04 and 0.06 %

15 The morphological purity of the product (according to X-ray diffraction method): 100% amorphous

Example 3

Synthesis of amorphous atorvastatin calcium

20 7.3 g (0.01 mol) of L-arginine salt of atorvastatin acid is dissolved in a mixture of 50 ml of distilled water and 20 ml of 2-propanol at 40°C. A solution of 0.9 g of calcium acetate hydrate in 10 ml of distilled water is added to the solution at this temperature and cooled to 0-5°C. The obtained suspension is stirred at 0-5°C for 1h,
25 then the product is filtered, washed with a 5:2 mixture of distilled water and 2-propanol (2 x 10 ml) and dried at max. 50°C.

The obtained product is: 5.1 g (88%) amorphous atorvastatin calcium

The chemical purity of the product is: 99.9 %

Total amount of impurities is: below 0.10 %

30 The morphological purity of the product (according to X-ray diffraction method): 100% amorphous

Example 4

Methods for measuring the purity of products obtained in Example 1-3:

A/ HPLC method:5 Colonna: YMC-Pack Pro C18, 150x4.6mm ID, 5 μ mEluent: A: 100 ml of acetonitrile + 895 ml of distilled water +
5 ml of 1 M/dm³ TEAPB: 900 ml of acetonitrile + 95 ml of distilled water + 5
ml of 1 M/dm³ TEAP10 (TEAP: triethylammonium phosphate buffer, Fluka
Chemie, cat.no.: 90362)

Gradient:

Time (min)	A%	B%
0	100	0
5	40	60
10	40	60
15	15	85
18	5	95
26	5	95
26,1	100	0
31	100	0

15 Detection: for 26 min

Wavelength: 215 nm

Temperature: room temperature

Injected volume: 10 μ l

Flow-rate: 1.0 ml/min

20 Samples were dissolved in a mixture of acetonitrile : distilled water = 1:1, concentration
0.8 mg/ml

B/ X-ray diffraction method

The study was carried out by Philips PW 1840 powder diffractometer using the following parameters:

- CuK α radiation: 30 kV, 30 mA
5 Goniometer speed: 0.05 °2 θ /s
Sensitivity: 2 x 10³ cps
T.C.: 5 seconds
Gap width: 0.05 mm

- 10 According to the obtained powder diagram (Figure 1) the sample is amorphous, there are no diffraction peaks in the powder diagram

Example 5

- 15 HPLC chromatogram of the product obtained in Example 2:


(See: Figure 2)

Data of chromatogram:



- 20 11.423 min, RRT: 0.96: 0.03 area %
11.683 min, RRT: 0.98: 0.04 area %
14.342 min, RRT: 1.20: 0.06 area %

What we claim is:

1. A process for the synthesis of amorphous atorvastatin calcium characterized by dissolving the salt of the formula (I) of atorvastatin acid formed with a basic amino acid



— wherein the meaning of R is the compound of formula (II) or (III)



– in a mixture of water and a water miscible organic solvent, adding an aqueous solution of a water soluble calcium salt to the solution and isolating the so obtained entirely amorphous atorvastatin calcium of high purity by filtration.

5

2. The process according to claim 1, characterized by using calcium acetate or calcium chloride as water soluble calcium salt.
3. The process according to claims 1 and 2, characterized by using methanol,

10

ethanol, isopropanol or acetone as water miscible organic solvent.




Fig. 1.




FIG. 2

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/HU2004/000026

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D207/34 A61K31/00 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/28999 A (EGYT GYOGYSZERVEGYEZETI GYAR ; SZENT KIRALLYI ZSUZSA (HU); VERECZKEYN) 26 April 2001 (2001-04-26) cited in the application examples	1-3
A	WO 01/42209 A (LEK TOVARNA FARMACEVTSKIH ; PFLAUM ZLATKO (SI)) 14 June 2001 (2001-06-14) examples	1-3
P,A	WO 03/082816 A (LANCZOS KRISZTINA ; ERDELYI PETER (HU); FISCHER JANOS (HU); HEGEDUES B) 9 October 2003 (2003-10-09) the whole document	1-3

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the International search

23 July 2004

Date of mailing of the International search report

04/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Menegaki, F

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/HU2004/000026

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0128999	A	26-04-2001	HU 9903634 A2	28-12-2001
			AU 1166301 A	30-04-2001
			CA 2388018 A1	26-04-2001
			CN 1379760 T	13-11-2002
			CZ 20021256 A3	14-08-2002
			EP 1235800 A1	04-09-2002
			HR 20020334 A2	29-02-2004
			WO 0128999 A1	26-04-2001
			JP 2003512354 T	02-04-2003
			PL 354604 A1	26-01-2004
			SK 5192002 A3	06-11-2002
			US 2004063969 A1	01-04-2004
WO 0142209	A	14-06-2001	SI 20425 A	30-06-2001
			AU 1543801 A	18-06-2001
			BG 106786 A	30-05-2003
			CA 2392025 A1	14-06-2001
			EE 200200293 A	16-06-2003
			EP 1237864 A1	11-09-2002
			WO 0142209 A1	14-06-2001
			JP 2003516388 T	13-05-2003
			SK 7832002 A3	06-11-2002
			US 2002183527 A1	05-12-2002
			US 2004024046 A1	05-02-2004
WO 03082816	A	09-10-2003	HU 0201083 A2	28-06-2004
			WO 03082816 A1	09-10-2003